What we are researching
The purpose of this study is to find out how effective and safe different doses of the study medicine are in treating people with type 2 diabetes.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07668388.
Type 2 Diabetes
Have been diagnosed with type 2 diabetes, at least 180 days (about 6 months) before joining the study
Current Treatment
Be on a stable dose of metformin with or without an SGLT2 inhibitor for at least 90 days before joining the study
Body Weight
Have a body mass index (BMI) of 25 to 50
Age
18 to 75 years
Study Medicine
Once weekly injection
Number of study visits
About 36 visits over a period of about 12 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be randomly assigned to receive either the study medicine at one of five dose levels, an active comparator medicine, or placebo (which has no active medicine in it). All are given as injections under the skin, using an injection pen. Your study team will teach you how to use the injection pen.
Your participation is expected to last about 1 year, with a mix of in-person and phone visits every 1-2 weeks. These visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8577
You may also choose to discuss this clinical trial with your healthcare provider.